<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">6285947</article-id><article-id pub-id-type="pmc">2011055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Urtasun</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Feldstein</surname><given-names>M. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Partington</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tanasichuk</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>J. D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Russell</surname><given-names>D. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Agboola</surname><given-names>O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mielke</surname><given-names>B.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><month>7</month><year>1982</year></pub-date><volume>46</volume><issue>1</issue><fpage>101</fpage><lpage>108</lpage><abstract><p>As a continuation of a previous controlled trial using "high-dose" metronidazole as a specific sensitizer of hypoxic cells, we used a more efficient nitroimidazole derivative (misonidazole, MISO) in combination with higher doses of radiation in patients with supratentorial high-grade astrocytomas. Sixty-six patients were stratified according to functional level and histological grading, and randomly allocated within 2 weeks of operation of 1 of 3 therapeutic groups: 1, conventional radiation alone; 2, large fractions of radiation with high-dose metronidazole; and 3, radiation as in Group 2 but with equitoxic doses of MISO. We examined survival as the principal end-point of the study. Neither by increasing the dose of radiation over the previous study, nor by using a more efficient sensitizer, were we able to improve survival over the current conventional daily fractionated radiation.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00430-0112.tif" xlink:title="scanned-page" xlink:role="101" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0113.tif" xlink:title="scanned-page" xlink:role="102" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0114.tif" xlink:title="scanned-page" xlink:role="103" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0115.tif" xlink:title="scanned-page" xlink:role="104" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0116.tif" xlink:title="scanned-page" xlink:role="105" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0117.tif" xlink:title="scanned-page" xlink:role="106" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0118.tif" xlink:title="scanned-page" xlink:role="107" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00430-0119.tif" xlink:title="scanned-page" xlink:role="108" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

